Elacridar

Overview

Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein ( BCRP ) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > P-glycoprotein | Products > Signaling Pathways > BCRP

Product Information

• Catalog No.: HY-50879
• CAS No.: 143664-11-3
• Molecular Formula: C34H33N3O5
• Molecular Weight: 563.64
• Purity: 99.66%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 1.67 mg/mL (2.96 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source